A Phase 2 interventional study of SyB L-0501 and rituximab in Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated, sponsored by SymBio Pharmaceuticals. Completed at 14 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2016-04-27.
Sponsored by SymBio Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing bendamustine in Lymphoma, Mantle-Cell — 2 open to participants now, 7 under way, 1 of them phase 3. bendamustine · Lymphoma, Mantle-Cell.
Among the 32 studies testing bendamustine in Lymphoma, Mantle-Cell, this one is the 4th largest by enrollment, is one of 2 that started in 2011, is one of 16 in phase 2, and was the 20th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →2 of the 32 studies testing bendamustine in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18–80
Czech Lymphoma Study Group · Sites in Czechia
Ages 18–80
By country, each count listing its studies:
bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 21 · Phase 3 3
First in 2007; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 42 across the 32 interventional studies. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 32 have an industry lead sponsor. The 10 most frequent:
SymBio Pharmaceuticals is the lead sponsor of 25 studies on the registry; 1 is open to participants now.
SymBio Pharmaceuticals has 4 studies filed under Lymphoma, Mantle-Cell — fewer than ten, so there is no comparison to draw.
3 of the studies testing bendamustine in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06496308Phase 3Ruijin HospitalBendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | 2027-07-10 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT02153580City of Hope Medical CenterCellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | 2027-08-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing bendamustine in Lymphoma, Mantle-Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of SyB L-0501 (two-day consecutive 90 mg/m2/day IV drip infusions) in combination with rituximab (375 mg/m2 IV drip infusion) on untreated, low-grade B cell non-Hodgkin's lymphoma and mantle cell lymphoma where hematopoietic stem cell transplantation is not indicated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who are histopathologically confirmed to have the following cluster of differentiation 20 (CD20) positive low-grade B cell non-Hodgkin's lymphoma or mantle cell lymphoma by lymph node or evaluable tissue biopsy within 6 months before the registration WHO Classification of Tumors (fourth edition):
Patients with at least 1 of the following clinical symptoms or signs (excluding mantle cell lymphoma):
B symptoms
Patients with adequately maintained major organ function (bone marrow, heart, lungs, liver, kidneys)
Exclusion Criteria:
Patients who fall under any one of the following criteria are to be excluded
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SyB L-0501 · Drug: rituximab
A dose of 90 mg/m\^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
A dose of 375 mg/m\^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)
The criteria for CR and CRu based on IWRC are shown below. CR: Fulfills all of the following * Disappearance of all detectable disease * LN\* \> 1.5 cm must decrease to ≤ 1.5 cm CRu: Fulfills all of the following * LN \>1.5 cm; SPD\*\* decrease \>75% * indeterminate bone marrow * LN: lymph nodes or nodal masses \*\* SPD: sum of the products of the greatest diameters
Time frame: Up to 30 weeks
Overall Response Rate (Antitumor Effect: PR or Better) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)
The criteria for PR based on IWRC are shown below. PR: SPD regressed \> 50%
Time frame: Up to 30 weeks
Complete Response Rate (CR) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)
The criteria for CR based on the Revised RC are shown below. Definition: Disappearance of all evidence of disease Nodal Masses: 1. \[18F\]fluorodeoxyglucose (FDG)-avid or PET positive prior to therapy; mass of any size permitted if PET negative. 2. Variably FDG-avid or PET negative; regression to normal size on CT. Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.
Time frame: Up to 30 weeks
Overall Response Rate (PR or Better) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)
The criteria for PR based on the Revised RC are shown below. Definition: Regression of measurable disease and no new sites Nodal Masses: 50% or more decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes 1. FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site 2. Variably FDG-avid or PET negative; regression on CT Spleen, Liver: 50% or more decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.
Time frame: Up to 30 weeks
Complete Response Rate Based on WHO Handbook for Reporting Results of Cancer Treatment (1979)
The criteria for Complete response based on WHO Handbook for Reporting Results of Cancer Treatment (1979) are shown below. Measurable disease: The disappearance of all known disease, determined by 2 observations not less than 4 weeks apart. Unmeasurable disease: Complete disappearance of all known disease for at least 4 weeks. Bone metastases: Complete disappearance of all lesions on X-ray or scan for at least 4 weeks.
Time frame: Up to 30 weeks
Overall Response Rate (PR or Better) Based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)"
The criteria for Overall response rate (PR or better) based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)" are shown below. Definition of PR: Measurable disease: 50% or more decrease in total tumor size of the lesions which have been measured to determine the effect of therapy by 2 observations not less than 4 weeks apart. In addition there can be no appearance of new lesions or progression of any lesion. Unmeasurable disease: Estimated decrease in tumor size of 50% or more for at least 4 weeks. Bone metastases: Partial decrease in size of lytic lesions, recalcification of lytic lesions, or decreased density of blastic lesions for at least 4 weeks.
Time frame: Up to 30 weeks
Progression-Free Survival (PFS)
PFS is the period from registration date to the earliest onset date of any progression event calculated using the Kaplan-Meier estimator. The median and the 95% confidence interval (CI) were calculated using Greenwood's formula. Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause. The date of progression was determined based on overall response assessed using IWRC, Revised RC, and WHO, and assessment by the primary physicians (excluding overall response).
Time frame: Up to 30 weeks
Duration of Response (DOR)
DOR is the period from the date of achieving CR, CRu or PR in the responders to the earliest onset date of any progression events calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula. The date of achieving CR, CRu or PR was determined based on the overall response assessed using IWRC. The date of progression was determined based on overall response assessed using IWRC, Revised RC and WHO, and assessment by the primary physicians (excluding overall response). Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause.
Time frame: Up to 30 weeks
Overall Survival (OS)
Death due to any given cause was defined as an event. OS was calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula.
Time frame: Up to 30 weeks
Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Discontinuation Due to Adverse Event
Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.0, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA) Ver.16.1.
Time frame: up to 30 weeks
Laboratory Test Abnormalities (Biochemical Tests)
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE
Time frame: up to 30 weeks
Laboratory Test Abnormalities (Hematology Tests)
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE
Time frame: up to 30 weeks
| Milestone | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma |
|---|---|---|
| Started | 60 | 10 |
| Completed | 42 | 9 |
| Not completed | 18 | 1 |
The criteria for CR and CRu based on IWRC are shown below. CR: Fulfills all of the following * Disappearance of all detectable disease * LN\* \> 1.5 cm must decrease to ≤ 1.5 cm CRu: Fulfills all of the following * LN \>1.5 cm; SPD\*\* decrease \>75% * indeterminate bone marrow * LN: lymph nodes or nodal masses \*\* SPD: sum of the products of the greatest diameters
| percentage of participants | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) | 67.8 | 70.0 | 68.1 |
The criteria for PR based on IWRC are shown below. PR: SPD regressed \> 50%
| percentage of participants | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Overall Response Rate (Antitumor Effect: PR or Better) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) | 96.6 | 90.0 | 95.7 |
The criteria for CR based on the Revised RC are shown below. Definition: Disappearance of all evidence of disease Nodal Masses: 1. \[18F\]fluorodeoxyglucose (FDG)-avid or PET positive prior to therapy; mass of any size permitted if PET negative. 2. Variably FDG-avid or PET negative; regression to normal size on CT. Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative.
| percentage of participants | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Complete Response Rate (CR) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC) | 64.4 | 80.0 | 66.7 |
The criteria for PR based on the Revised RC are shown below. Definition: Regression of measurable disease and no new sites Nodal Masses: 50% or more decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes 1. FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site 2. Variably FDG-avid or PET negative; regression on CT Spleen, Liver: 50% or more decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.
| percentage of participants | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Overall Response Rate (PR or Better) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC) | 96.6 | 90.0 | 95.7 |
The criteria for Complete response based on WHO Handbook for Reporting Results of Cancer Treatment (1979) are shown below. Measurable disease: The disappearance of all known disease, determined by 2 observations not less than 4 weeks apart. Unmeasurable disease: Complete disappearance of all known disease for at least 4 weeks. Bone metastases: Complete disappearance of all lesions on X-ray or scan for at least 4 weeks.
| percentage of participants | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Complete Response Rate Based on WHO Handbook for Reporting Results of Cancer Treatment (1979) | 22.0 | 40.0 | 24.6 |
The criteria for Overall response rate (PR or better) based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)" are shown below. Definition of PR: Measurable disease: 50% or more decrease in total tumor size of the lesions which have been measured to determine the effect of therapy by 2 observations not less than 4 weeks apart. In addition there can be no appearance of new lesions or progression of any lesion. Unmeasurable disease: Estimated decrease in tumor size of 50% or more for at least 4 weeks. Bone metastases: Partial decrease in size of lytic lesions, recalcification of lytic lesions, or decreased density of blastic lesions for at least 4 weeks.
| percentage of participants | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Overall Response Rate (PR or Better) Based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)" | 86.4 | 90.0 | 87.0 |
PFS is the period from registration date to the earliest onset date of any progression event calculated using the Kaplan-Meier estimator. The median and the 95% confidence interval (CI) were calculated using Greenwood's formula. Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause. The date of progression was determined based on overall response assessed using IWRC, Revised RC, and WHO, and assessment by the primary physicians (excluding overall response).
| days | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Progression-Free Survival (PFS) | NA (654.0 to NA) | NA (NA to NA) | NA (654.0 to NA) |
DOR is the period from the date of achieving CR, CRu or PR in the responders to the earliest onset date of any progression events calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula. The date of achieving CR, CRu or PR was determined based on the overall response assessed using IWRC. The date of progression was determined based on overall response assessed using IWRC, Revised RC and WHO, and assessment by the primary physicians (excluding overall response). Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause.
| days | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Duration of Response (DOR) | NA (541.0 to NA) | NA (NA to NA) | NA (541.0 to NA) |
Death due to any given cause was defined as an event. OS was calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula.
| days | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.0, Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA) Ver.16.1.
| participants | Total |
|---|---|
| Any adverse event | 69 |
| Adverse drug reaction | 69 |
| SAE | 9 |
| Death | 0 |
| Discontinuation due to adverse events | 0 |
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE
| participants | Total |
|---|---|
| Grade 3 : AST(GOT) | 3 |
| Grade 3 : ALT(GPT) | 3 |
| Grade 3 : γ-GTP | 1 |
| Grade 4 : Uric acid | 1 |
| Grade 3 : Na decrease | 1 |
| Grade 3 : K decrease | 2 |
| Grade 3 : K increase | 1 |
Abnormalities in laboratory test values in overall study period were analyzed. Severity of abnormalities were evaluated using CTCAE. Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE
| participants | Total |
|---|---|
| Grade 3 : White blood cell count decreased | 45 |
| Grade 4 : White blood cell count decreased | 12 |
| Grade 3 : Neutrophil count decreased | 25 |
| Grade 4 : Neutrophil count decreased | 34 |
| Grade 3 : Lymphocyte count decreased | 6 |
| Grade 4 : Lymphocyte count decreased | 63 |
| Grade 3 : Haemoglobin decreased | 5 |
| Grade 3 : Platelet count decreased | 3 |
| Grade 4 : Platelet count decreased | 2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SyB L-0501+Rituximab | — | 9/69 (13%) | 69/69 (100%) |
| Event | SyB L-0501+Rituximab |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/69 |
| tumour lysis syndromeMetabolism and nutrition disorders | 1/69 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/69 |
| pneumonia cytomegaloviralInfections and infestations | 1/69 |
| dermatitis allergicSkin and subcutaneous tissue disorders | 1/69 |
| cytogenetic abnormalityCongenital, familial and genetic disorders | 1/69 |
| atrial tachycardiaCardiac disorders | 1/69 |
| pyrexiaGeneral disorders | 1/69 |
| Event | SyB L-0501+Rituximab |
|---|---|
| White blood cell count decreasedInvestigations | 69/69 |
| Lymphocyte count decreasedInvestigations | 67/69 |
| Neutrophil count decreasedInvestigations | 65/69 |
| CD4 lymphocytes decreasedInvestigations | 64/69 |
| NauseaGastrointestinal disorders | 46/69 |
| ConstipationGastrointestinal disorders | 45/69 |
| Platelet count decreasedInvestigations | 38/69 |
| MalaiseGeneral disorders | 37/69 |
| Blood immunoglobulin M decreasedInvestigations | 32/69 |
| Decreased appetiteMetabolism and nutrition disorders | 30/69 |
Of the 70 subjects enrolled, one who did not receive the investigational product was excluded. Therefore, the total number of Baseline Participants is 69.
| Age, Customized(participants) | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| ˂65 years | 36 | 0 | 36 |
| ≥65 years | 23 | 10 | 33 |
| Sex: Female, Male(Participants) | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Female | 37 | 1 | 38 |
| Male | 22 | 9 | 31 |
| Performance status (ECOG scale)(participants) | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| 0 | 42 | 7 | 49 |
| 1 | 16 | 3 | 19 |
| 2 | 1 | 0 | 1 |
| Diagnosis (WHO classification)(participants) | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| Small lymphocytic lymphoma | 2 | 0 | 2 |
| Lymphoplasmacytic lymphoma | 2 | 0 | 2 |
| Splenic marginal zone lymphoma | 0 | 0 | 0 |
| B-EMZL(MALT lymphoma) | 4 | 0 | 4 |
| Nodal marginal zone B-cell lymphoma | 0 | 0 | 0 |
| Follicular lymphoma | 51 | 0 | 51 |
| Mantle cell lymphoma | 0 | 10 | 10 |
| Clinical stage (Ann Arbor staging classification)(participants) | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| I - II | 15 | 0 | 15 |
| III | 9 | 0 | 9 |
| IV | 35 | 10 | 45 |
| Number of lymph node regions(participants) | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| 0 region | 0 | 0 | 0 |
| 1 region | 12 | 1 | 13 |
| 2 regions | 6 | 1 | 7 |
| 3 regions | 4 | 2 | 6 |
| 4 regions or more | 37 | 6 | 43 |
| Number of extranodal lesions(participants) | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| 0 - 1 lesion | 50 | 4 | 54 |
| 2 or more lesions | 9 | 6 | 15 |
| Tumor diameter (1)(participants) | Low-grade B-cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Total |
|---|---|---|---|
| ≥5 cm | 38 | 4 | 42 |
| ˂5 cm | 21 | 6 | 27 |
19 further baseline measures are reported on the registry.
The record gives a start of Nov 2011, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bendamustine · Rituximab